The company's platforms include Chimpanzee Adenovirus Oxford (ChAdOx) and Modified vaccinia Ankara (MVA), two viral vectors which safely mimic viral infection in human cells and elicit antibody and T cell responses to pathogens and tumours,[3] as well as two SNAP synthetic platforms, SNAP-TI (SNAP-Tolerance Immunotherapy) and SNAP-CI (SNAP-Cancer Immunotherapy), previously referred to collectively as SNAPvaxTM.

[4][5][6] Vaccitech has been financed and supported by M&G Catalyst, Google Ventures (GV), Fosun International, Tencent, Huawei, Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).

[7][8][9] In early 2020, Vaccitech and the University of Oxford co-invented a vaccine for COVID-19 using the ChAdOx platform.

[citation needed] In July 2020, it was reported that people in Brazil, South Africa and the US had been recruited to populate the vaccine trials.

Vaccitech held an initial public offering of shares in 2021, listing on NASDAQ on 30 April 2021.